# John Shields

> John Shields is a Series A investor at Abingworth backing Therapeutics and Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Abingworth](https://shizune.co/investors/profile/abingworth-management)
- Total investments: 1
- Last investment: Oct 2017
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/john-shields-a05028a

John Shields is a Series A investor at Abingworth focused on Therapeutics and Biotechnology. John has 13 years of operational experience in life science companies. He joined Abingworth in 2001 from Cantab Pharmaceuticals where he was Senior Vice President, Research. He had a strong role in business development and played a significant part in the in-licensing of new products and technologies to the firm. Prior to Cantab, he was at theGlaxo Institute for Molecular Biology in Geneva, Switzerland. From 1982 to 1988, he held research positions at the Institute of Child Health, the University of London, UK. John has a PhD in Immunology from the University of Glasgow. He has published more than 30 papers in peer-reviewed journals including Science. At Abingworth, John is involved with scientific evaluation of new and existing investments and works closely with UK universities and early-stage companies.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| VirionHealth | VirionHealth is a biotechnology company developing ground-breaking therapies for respiratory viral infections. Its pioneering DI platform technology will provide a new class of biological antiviral active across a range of infectious diseases. | $17M | Series A | Oct 12, 2017 |  |

1 of 1 investments shown.

## About Abingworth

VC Fund · London, United Kingdom

Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciencessectors.Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.

5 contacts available at Abingworth.

| Name | Title | Profile |
| --- | --- | --- |
| Brian Gallagher | Partner | https://shizune.co/investors/profile/brian-gallagher |
| John Shields | Advisor, Science and Technology | https://shizune.co/investors/profile/john-shields |
| Quentin Lloyd-Harris | Partner | https://shizune.co/investors/profile/genghis-lloyd-harris |
| Alex Asquith | General Counsel and Chief Financial Officer | https://shizune.co/investors/profile/alex-asquith |
| Andrew Sinclair | Partner & Portfolio Manager | https://shizune.co/investors/profile/andrew-sinclair |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does John Shields invest in?

John Shields invests primarily in Therapeutics, Biotechnology and Pharmaceutical startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did John Shields last invest?

The most recent investment recorded for John Shields closed in Oct 2017. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co